Crescendo Bioscience Announces that New Studies with Vectra® DA Data Will Be Presented at the American College of Rheumatology 2015 Annual Meeting

Studies Highlight Vectra DA for Assessing Treatment Response in Rheumatoid Arthritis SALT LAKE CITY, Utah, Nov. 7, 2015 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that new data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at […]

Read More

Crescendo Bioscience Highlights New Studies with Vectra® DA that Will Be Presented at the American College of Rheumatology 2015 Annual Meeting

SALT LAKE CITY, Utah, Oct. 22, 2015 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that new data on Vectra DA will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) meeting being held Nov. 7-11, 2015 in San Francisco, Calif. A list of the […]

Read More

Crescendo Bioscience Names Elena Hitraya M.D., Ph.D., as Chief Medical Officer

Former Group Medical Director of Rheumatology Medical Affairs at Genentech Joins Leadership Team SALT LAKE CITY, Sept. 1, 2015 (GLOBE NEWSWIRE) — Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), announced that Elena Hitraya M.D., Ph.D., has joined the Company as the chief medical officer of Crescendo Bioscience, effective October 1, 2015. She […]

Read More

Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience

Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience Former Amgen and Eli Lilly Executive Joins Crescendo Leadership Team SALT LAKE CITY, Dec. 22, 2014 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the appointment of Bernard F. Tobin as president of Crescendo Bioscience, effective January 5, 2015. Mr. Tobin will report to […]

Read More